Physiomics Announces License Agreement with Eli Lilly
Physiomics announced that it has signed a license agreement with Eli Lilly and Company. Under the terms of the agreement, Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.
‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.